non-alcoholic steatohepatitis (nash) research tools...= 1 µm); reduces nf-κb signaling in...

2
1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · [800] 364-9897 WWW.CAYMANCHEM.COM 2017 Non-Alcoholic Steatohepas (NASH) Research Tools Non-alcoholic steatohepas (NASH) is a type of non-alcoholic fay liver disease (NAFLD) characterized by abnormal accumulaon of lipids and cellular damage, and the presence of sustained inflammaon within the liver. NASH can progress further to more chronic condions such as fibrosis, cirrhosis, and even hepatocellular carcinoma. The molecular mechanisms involved in the development and progression of NASH remain poorly understood. Cayman offers a range of biochemical tools and assay kits to assist invesgators in their study of this growing health problem. Biochemicals Item No. Product Name Descripon 11686 Betulinic Acid TGR5 agonist (EC 50 = 1 µM); reduces NF-κB signaling in LPS-treated macrophages and increases ABCA1 expression 12032 BI6015 HNF4α antagonist that causes dose-dependent fat accumulaon (steatosis) in liver 10008335 all-cis-4,7,10,13,16-Docosapentaenoic Acid DPA isomer; concentraons increased in NASH 16624 GPR120 Compound A Decreases hepac steatosis when included at 30 mg/kg body weight in a high-fat diet fed to obese mice 17678 INT-777 TGR5 agonist (EC 50 = 0.82 µM); reduces hepac steatosis and adiposity in mice subjected to diet-induced obesity 10739 Isoliquirigenin Exhibits anoxidant, an-inflammatory, and antumor acvies, as well as hepatoprotecon against steatosis-induced oxidave stress 13118 Meormin (hydrochloride) Improves fay liver disease by reversing hepac steatosis in ob/ob mice 18293 MHY908 Improves hepac steatosis by enhancing CPT1 levels and reducing ER stress and JNK acvaon in livers of db/db mice 15192 ML-261 Inhibits hepac lipid droplet formaon (IC 50 = 69.7 nM in mouse AML-12 hepatocytes) 14173 Naringenin Corrects VLDL overproducon, ameliorates hepac steatosis, and aenuates dyslipidemia in LDL receptor-deficient mice fed a Western diet 17118 Niclosamide (ethanolamine salt) Prevents high-fat diet-induced hepac steatosis in db/db mice 19131 NK 252 Exhibits anfibroc effects in a rat model of NASH 16209 p-nitro-Pifithrin-α Aenuates steatosis and liver injury in mice fed a high-fat diet 18771 SR9238 LXRα and LXRβ inverse agonist (IC 50 s = 214 and 43 nM, respecvely); suppresses hepac lipogenesis, inflammaon, lipid accumulaon, and fibrosis in mouse models of NASH 16291 TGR5 Receptor Agonist Acvator of TGR5 (pEC 50 = 6.8-7.5); increases GLP-1 secreon and improves glucose disposal View a complete list of our tools for metabolism research at www.caymanchem.com

Upload: others

Post on 10-Aug-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Non-Alcoholic Steatohepatitis (NASH) Research Tools...= 1 µM); reduces NF-κB signaling in LPS-treated macrophages and increases ABCA1 expression 12032 BI6015 HNF4α antagonist that

1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · [800] 364-9897 WWW.CAYMANCHEM.COM2017

Non-Alcoholic Steatohepatitis (NASH)Research ToolsNon-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) characterized by abnormal accumulation of lipids and cellular damage, and the presence of sustained inflammation within the liver. NASH can progress further to more chronic conditions such as fibrosis, cirrhosis, and even hepatocellular carcinoma. The molecular mechanisms involved in the development and progression of NASH remain poorly understood. Cayman offers a range of biochemical tools and assay kits to assist investigators in their study of this growing health problem.

BiochemicalsItem No. Product Name Description

11686 Betulinic Acid TGR5 agonist (EC50 = 1 µM); reduces NF-κB signaling in LPS-treated macrophages and increases ABCA1 expression

12032 BI6015 HNF4α antagonist that causes dose-dependent fat accumulation (steatosis) in liver

10008335 all-cis-4,7,10,13,16-Docosapentaenoic Acid DPA isomer; concentrations increased in NASH

16624 GPR120 Compound A Decreases hepatic steatosis when included at 30 mg/kg body weight in a high-fat diet fed to obese mice

17678 INT-777 TGR5 agonist (EC50 = 0.82 µM); reduces hepatic steatosis and adiposity in mice subjected to diet-induced obesity

10739 Isoliquiritigenin Exhibits antioxidant, anti-inflammatory, and antitumor activities, as well as hepatoprotection against steatosis-induced oxidative stress

13118 Metformin (hydrochloride) Improves fatty liver disease by reversing hepatic steatosis in ob/ob mice

18293 MHY908 Improves hepatic steatosis by enhancing CPT1 levels and reducing ER stress and JNK activation in livers of db/db mice

15192 ML-261 Inhibits hepatic lipid droplet formation (IC50 = 69.7 nM in mouse AML-12 hepatocytes)

14173 Naringenin Corrects VLDL overproduction, ameliorates hepatic steatosis, and attenuates dyslipidemia in LDL receptor-deficient mice fed a Western diet

17118 Niclosamide (ethanolamine salt) Prevents high-fat diet-induced hepatic steatosis in db/db mice

19131 NK 252 Exhibits antifibrotic effects in a rat model of NASH

16209 p-nitro-Pifithrin-α Attenuates steatosis and liver injury in mice fed a high-fat diet

18771 SR9238 LXRα and LXRβ inverse agonist (IC50s = 214 and 43 nM, respectively); suppresses hepaticlipogenesis, inflammation, lipid accumulation, and fibrosis in mouse models of NASH

16291 TGR5 Receptor Agonist Activator of TGR5 (pEC50 = 6.8-7.5); increases GLP-1 secretion and improves glucose disposal

View a complete list of our tools for metabolism research at www.caymanchem.com

Page 2: Non-Alcoholic Steatohepatitis (NASH) Research Tools...= 1 µM); reduces NF-κB signaling in LPS-treated macrophages and increases ABCA1 expression 12032 BI6015 HNF4α antagonist that

1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · [800] 364-9897 WWW.CAYMANCHEM.COM2017

Non-Alcoholic Steatohepatitis (NASH)Research Tools

Assays KitsItem No. Product Name Description

700260 Alanine Transaminase Colorimetric Activity Assay Kit

Convenient method for measuring alanine transaminase activity levels in serum, plasma, tissue, and cell lysates

10007640 Cholesterol Fluorometric Assay Kit Plate-based assay for quantifying total cholesterol in plasma or serum

700310 Free Fatty Acid Fluorometric Assay Kit Fluorescence-based method for measuring free fatty acid in plasma, serum, and urine

501030 Interleukin-6 (human) ELISA Kit Measure interleukin-6 in human plasma, serum, synovial fluid, and other sample matrices

500001 Lipid Droplets Fluorescence Assay Kit Fluorescence-based method for sensitive detection of cellular lipid droplets

589201 TNF-α (human) ELISA Kit Sensitive, specific ELISA for measuring TNF-α in human plasma, serum, and other sample matrices

500850 TNF-α (mouse) ELISA Kit Sensitive, specific ELISA for measuring TNF-α in mouse plasma, serum, and other sample matrices

10010303 Triglyceride Colorimetric Assay Kit Simple assay for measuring triglyceride levels in plasma, serum, cell lysates, and tissue homogenates

Steatosis Colorimetric Assay KitItem No. 10012643

Features:• Detect excessive lipid accumulation in cells

• Assess by microscopy or plate reader

• An inducer of lipid accumulation is included as a positive control

FEATURED ASSAY

Effect of chloroquine on lipid droplet accumulation in HepG2 cells. HepG2 cells were seeded at a density of 104 cells/well in a 96-well plate and grown in a 37˚C incubator overnight. The next day, cells were treated with vehicle or different doses of chloroquine for three days. Panel A: HepG2 cells treated with vehicle. There are a few lipid droplets in the cells, appearing as red dots. Panel B: HepG2 cells treated with 25 µM chloroquine show significant accumulation of lipid droplets, evident by abundant appearance of red dots visualized by Oil Red O staining.

A BEffect of chloroquine on lipid droplet accumulation in HepG2 cells. HepG2 cells were seeded at a density of 104 cells/well in a 96-well plate and grown in a 37˚C incubator overnight. The next day, cells were treated with vehicle or different doses of chloroquine for three days. Panel A: HepG2 cells treated with vehicle. There are a few lipid droplets in the cells, appearing as red dots. Panel B: HepG2 cells treated with 25 µM chloroquine show significant accumulation of lipid droplets, evident by abundant appearance of red dots visualized by Oil Red O staining.

A BEffect of chloroquine on lipid droplet accumulation in HepG2 cells. Panel A: HepG2 cells treated with vehicle. Panel B: HepG2 cells treated with 25 µM chloroquine show significant accumulation of lipid droplets (red dots) visualized by Oil Red O staining.

View a complete list of our tools for metabolism research at www.caymanchem.comDistributed by:

フナコシ株式会社

〒113-0033 東京都文京区本郷 2-9-7

http://www.funakoshi.co.jp

Tel:03-5684-1620

Fax:03-5684-1775

e-mail:[email protected]

http://www.funakoshi.co.jp

Tel: 03-5684-1620

Fax: 03-5684-1775

Email: [email protected]